Overview

An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Status:
Active, not recruiting

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This is an international, multicenter, open-label, randomized, Phase 3 study comparing the efficacy and safety of AG-221 versus conventional care regimens (CCRs) in subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase (IDH2) mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Celgene
Celgene Corporation

Treatments:

Azacitidine
Cytarabine